Androgen News and Research

RSS

PCEC releases statement on AUA's new prostate cancer clinical practice guidelines

The Prostate Conditions Education Council, a national organization committed to men's health and a leader in prostate cancer early detection, released the following statement in response to new clinical practice guideline released today by the American Urological Association.

5 May 2013

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

The well-studied protein VEGF does not appear to have any prognostic or predictive value for men with locally advanced prostate cancer, researchers from the Department of Radiation Oncology at Thomas Jefferson University Hospital and other institutions found in a retrospective study published online April 25 in the journal BMC Radiation Oncology.

30 Apr 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

29 Apr 2013

New risk classification system proposed for prostate cancer

US researchers have put forward a risk stratification system for patients with intermediate-risk prostate cancer undergoing dose-escalated external-beam radiation therapy.

25 Apr 2013

Research on soy-based treatment for colorectal cancer presented at AACR annual meeting

Research on a soy-based treatment for colorectal cancer, a promising agent in ovarian cancer, and a new drug target for advanced prostate cancer was presented at the American Association for Cancer Research 2013 Annual Meeting.

12 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

Study: microRNA is designed to stop proliferation of prostate cancer cells

The most recent in a series of studies from a team at the UC Davis Comprehensive Cancer Center has shown that a single molecule is at the heart of one of the most basic survival tactics of prostate cancer cells.

10 Apr 2013

Relationship between obesity and PCOS may be exaggerated, say researchers

The relationship between obesity and polycystic ovary syndrome may be exaggerated, likely because the women who actively seek care for the condition tend to be heavier than those identified through screening of the general population, researchers report.

9 Apr 2013

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

Taking a break from hormone-blocking prostate cancer treatments once the cancer seems to be stabilized is not equivalent to continuing therapy, a new large-scale international study finds.

4 Apr 2013

University of Maryland scientist selected as fellow of newly created AACR Academy

Angela H. Brodie, Ph.D., a University of Maryland scientist whose research paved the way for a new class of drugs widely used to treat breast cancer patients around the world, has been selected by the American Association for Cancer Research as a fellow of the newly created AACR Academy.

28 Mar 2013

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

DART Therapeutics Inc., an innovative, new-model biotechnology firm focused on developing therapies for Duchenne muscular dystrophy, announced today that it is developing a SARM drug candidate obtained from Belgium-based Galapagos NV.

21 Mar 2013

Study: Despite high erectile dysfunction prevalence most patients remain untreated

Despite the high erectile dysfunction prevalence most patients receive no treatment, according to a new US study, presented at the 28th Annual EAU Congress. Undertreatment of ED continues to be common, even though the treatments have a proven efficacy and quality of life impact.

19 Mar 2013

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

As part of an EU-supported IMI-PREDECT consortium, a Dutch study showed that anti-androgenic properties of the drug abiraterone may provide an additional mechanism of action in blocking tumour growth of castration resistant prostate cancer (CRPC).

16 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Prostate tissue androgen content predicts ADT outcome

Determining the androgen content in prostate tissue could predict patients’ responses to androgen deprivation therapy and the risk for castration-resistant prostate cancer, show study findings.

6 Mar 2013

Androgen deprivation therapy interferes with diabetes control

Androgen deprivation therapy for prostate cancer hampers glycemic control in men with diabetes, report researchers.

5 Mar 2013

Newborn screening improves detection of lethal form of congenital adrenal hyperplasia (CAH) in girls as well as boys

Contrary to current belief, routine newborn screening improves the detection of the lethal form of congenital adrenal hyperplasia (CAH) in girls as well as boys, saving lives in both sexes, according to a unique study of CAH during the last 100 years published Online First in The Lancet Diabetes and Endocrinology.

27 Feb 2013

Ampio Pharmaceuticals starts Optina clinical trial

Ampio Pharmaceuticals, Inc. announced oral dosing of the first patient in a 505(b)(2) clinical trial of the investigational drug Optina in diabetic macular edema.

27 Feb 2013

GCP could help lengthen life expectancy of certain prostate cancer patients

A natural, nontoxic product called genistein-combined polysaccharide, or GCP, which is commercially available in health stores, could help lengthen the life expectancy of certain prostate cancer patients, UC Davis researchers have found.

21 Feb 2013

Two different mechanisms trigger early-onset prostate cancers

While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which causes the disease at a later age.

12 Feb 2013

Androgen News and Research

PCEC releases statement on AUA's new prostate cancer clinical practice guidelines

Researchers find that VEGF may not have any prognostic value for advanced prostate cancer

New risk classification system proposed for prostate cancer

New risk classification system proposed for prostate cancer

Research on soy-based treatment for colorectal cancer presented at AACR annual meeting

Androgen receptors found to be a potential target in breast cancer

Study: microRNA is designed to stop proliferation of prostate cancer cells

Relationship between obesity and PCOS may be exaggerated, say researchers

Researchers study effectiveness of intermittent therapy for prostate cancer treatment

University of Maryland scientist selected as fellow of newly created AACR Academy

DART Therapeutics develops new class of therapy for Duchenne muscular dystrophy

Study: Despite high erectile dysfunction prevalence most patients remain untreated

Abiraterone's anti-androgenic properties may stop tumor growth of CRPC, says prize-winning Dutch study

Results from GTx's Phase 2 clinical trial of enobosarm published online

Prostate tissue androgen content predicts ADT outcome

Androgen deprivation therapy interferes with diabetes control

Newborn screening improves detection of lethal form of congenital adrenal hyperplasia (CAH) in girls as well as boys

Ampio Pharmaceuticals starts Optina clinical trial

GCP could help lengthen life expectancy of certain prostate cancer patients

Two different mechanisms trigger early-onset prostate cancers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News